ArticleAntimicrobial agents and chemotherapy2014
Pyocyanin production by Pseudomonas aeruginosa confers resistance to ionic silver.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Pyocyanin produced byAntimicrobial agents and chemotherapy · 2026Article
- Exclusion of catabolic regulation B (cbrB) gene in Pseudomonas aeruginosa attenuates the virulence at different glucose concentrations.BMC microbiology · 2026Article
- Role of AprA and pyocyanin fromMicrobiology (Reading, England) · 2025Article
- Silver-quercetin-loaded honeycomb-like Ti-based interface combats infection-triggered excessive inflammation via specific bactericidal and macrophage reprogramming.Bioactive materials · 2025Article
- Evaluation of expanded 2-aminobenzothiazole library as inhibitors of a model histidine kinase and virulence suppressors in Pseudomonas aeruginosa.Bioorganic chemistry · 2024Article
- Transforming microbial pigment into therapeutic revelation: extraction and characterization of pyocyanin from Pseudomonas aeruginosa and its therapeutic potential as an antibacterial and anticancer agent.Microbial cell factories · 2024Article
- A biomedical perspective of pyocyanin from Pseudomonas aeruginosa: its applications and challenges.World journal of microbiology & biotechnology · 2024Review
- The histidine kinase NahK regulates pyocyanin production through the PQS system.Journal of bacteriology · 2024Article
- Evaluation of Expanded 2-Aminobenzothiazole Library for Inhibition ofbioRxiv : the preprint server for biology · 2024Article
- Mechanisms of emerging resistance associated with non-antibiotic antimicrobial agents: a state-of-the-art review.The Journal of antibiotics · 2023Review
- Ceftazidime-assisted synthesis of ultrasmall chitosan nanoparticles for biofilm penetration and eradication of Pseudomonas aeruginosa.Scientific reports · 2023Article
- Pseudomonas aeruginosa's greenish-blue pigment pyocyanin: its production and biological activities.Microbial cell factories · 2023Review
- The efficacy of biosynthesized silver nanoparticles against Pseudomonas aeruginosa isolates from cystic fibrosis patients.Scientific reports · 2023Article
- Metals to combat antimicrobial resistance.Nature reviews. Chemistry · 2023Review
- Exploring the Co-Crystallization of Kojic Acid with Silver(I), Copper(II), Zinc(II), and Gallium(III) for Potential Antibacterial Applications.Molecules (Basel, Switzerland) · 2023Article
- Microbial silver resistance mechanisms: recent developments.World journal of microbiology & biotechnology · 2022Review
- Knocking down Pseudomonas aeruginosa virulence by oral hypoglycemic metformin nano emulsion.World journal of microbiology & biotechnology · 2022Article
- Microbiomics for enhancing electron transfer in an electrochemical system.Frontiers in microbiology · 2022Review
- Nanotechnology for Targeted Detection and Removal of Bacteria: Opportunities and Challenges.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Evolution of biofilm-forming pathogenic bacteria in the presence of nanoparticles and antibiotic: adaptation phenomena and cross-resistance.Journal of nanobiotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silver in its ionic form (Ag+), but not the bulk metal (Ag0), is toxic to microbial life forms and has been used for many years in the treatment of wound infections. The prevalence of bacterial resistance to silver is considered low due to the nonspecific nature of its toxicity. However, the recent increased use of silver as an antimicrobial agent for medical, consumer, and industrial products has raised concern that widespread silver resistance may emerge. Pseudomonas aeruginosa is a common pathogen that produces pyocyanin, a redox toxin and a reductant for molecular oxygen and ferric (Fe3+) ions. The objective of this study was to determine whether pyocyanin reduces Ag+ to Ag0, which may contribute to silver resistance due to lower bioavailability of the cation. Using surface plasmon resonance spectroscopy and scanning electron microscopy, pyocyanin was confirmed to be a reductant for Ag+, forming Ag0 nanoparticles and reducing the bioavailability of free Ag+ by >95% within minutes. Similarly, a pyocyanin-producing strain of P. aeruginosa (PA14) reduced Ag+ but not a pyocyanin-deficient (ΔphzM) strain of the bacterium. Challenge of each strain with Ag+ (as AgNO3) gave MICs of 20 and 5 μg/ml for the PA14 and ΔphzM strains, respectively. Removal of pyocyanin from the medium strain PA14 was grown in or its addition to the medium that ΔphzM mutant was grown in gave MICs of 5 and 20 μg/ml, respectively. Clinical isolates demonstrated similar pyocyanin-dependent resistance to Ag+. We conclude that pseudomonal silver resistance exists independently of previously recognized intracellular mechanisms and may be more prevalent than previously considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.